The Transformation of Multinational Pharmaceutical Companies in China: From Selling Drugs to Manufacturing Drugs – A Major Shift in China’s Role
Hello everyone, I’m your financial observer. Today, we’re not talking about the rise and fall of a single company, but rather a profound shift in the underlying logic of multinational pharmaceutical giants in the Chinese market.
If you follow the news, you might have noticed a trend: in the past, multinational pharmaceutical companies came to China mainly to tap into its vast patient population and reap market benefits. However, the situation has changed. They are no longer just focused on selling drugs; they are also vigorously investing in research and development, building factories, and even considering China as a global hub for innovation.
The core message of this news can be summarized in one sentence: “During a period of adjustment in the global pharmaceutical industry, the performance of multinational companies in China has seen a stark contrast—on one hand, innovative drugs are selling extremely well, driving significant growth in profits; on the other hand, the pressure from centralized government procurement (Jicai) has forced them to transform. The ultimate outcome is that China is evolving from a mere buyer to a partner in global pharmaceutical innovation.”
Let me break down this news into five key points to explain the behind-the-scenes dynamics in plain language.
---
1. The China International Import Expo (CIIE) as a “Accelerator” for Multinational Pharmaceutical Companies
The news repeatedly mentions the term “CIIE products.” This isn’t a term of endearment but refers to products that make their debut at the CIIE, are quickly launched in China, and then become bestsellers.
In the past: It could take several years, or even longer, for a new drug to go from global research and development to market entry in China.
Now: The CIIE has become a fast track.
- Example with Bayer: Their drugs for prostate cancer and kidney diseases saw sales increases of 56.6% and 79%, respectively. Many of these drugs were first showcased at the CIIE before being launched in the market.
- Example with AstraZeneca: Even more impressive, an innovative breast cancer drug completed the entire process—approval, market launch, and inclusion in the medical insurance system—in just 8 months after its debut at the CIIE.
What does this indicate? It shows that the efficiency of the Chinese market is improving. For multinational companies, the CIIE is no longer just a showcase but a strategic platform. Those who can launch products there can capture the attention of Chinese patients and quickly recoup their investment. This rapid transformation of products from exhibits to market-ready products is the reason why companies are willing to participate in the exhibition for nine consecutive years—it’s not just about the market; it’s about the speed benefits.
---
2. Divergent Performance: Innovative Drugs Are in High Demand, While Traditional Drugs Are Under Pressure from Jicai
The news highlights a clear divergence in performance:
- Flying high: Innovative drugs, such as Bayer’s kidney disease and AstraZeneca’s biopharmaceutical and oncology drugs, are seeing substantial sales growth due to their advanced technology and efficacy.
- Under pressure: Traditional generic drugs and mature medical devices are facing challenges from Jicai.
- Example with Medtronic: A leading company in cardiac pacemakers and orthopedic devices is still under pressure because Jicai has become the norm.
What does this mean? Jicai is essentially a price regulator, reducing the prices of well-established, competitively priced drugs, ending the era of easy profits for multinational companies.
---
3. From “Importers” to “Co-Developers”: China as a Global Innovation Hub
This is the most significant change mentioned in the news. Previously, multinational companies followed a model of developing drugs in the U.S. or Europe and then producing and selling them in China. Now, the approach has shifted to:
- Developing in China → Producing in China → Selling globally.
There are two concrete examples:
1. Medtronic’s “Shanghai Speed”:
- Signed a deal to set up operations in Lingang, Shanghai in 2021.
- Built the production line within a year.
- Got product approval by the end of 2025.
- Launched the product in 2026.
- The entire process took only 4 years! And these are domestically produced cardiac pacemakers.
This indicates that Medtronic is not just bringing over foreign technology; it’s leveraging China’s supply chain and talent to create globally competitive products.
2. Boehringer Ingelheim’s Structural Upgrade: China was once just one of their emerging markets, but now the Greater China region has been elevated to a key position, with the China president directly joining the global executive committee. They’ve established a new R&D center in Zhangjiang, Shanghai, focusing on early-stage development. Data shows that the Chinese team is involved in 75% of the company’s global early-stage projects, and it took only 7 days for a new drug to enter the first global trial.
What does this signify? China’s role in the global pharmaceutical supply chain has transformed. It’s no longer just a manufacturing hub; it’s now a center for innovation. Multinational companies are recognizing the competitiveness of Chinese scientists, clinical researchers, supply chains, and even the speed of patient recruitment. Instead of waiting in Europe, they’re innovating rapidly in China.
---
4. Strategic Shift: Focusing on Chronic Disease Management and the Entire Life Cycle
To adapt to Jicai pressures and market changes, multinational companies are reorienting their strategies. Both Bayer and Boehringer Ingelheim are shifting from focusing on treating acute illnesses to managing chronic diseases and providing comprehensive, lifelong care:
- Bayer’s Example: They’re moving from selling diabetes medications to helping patients manage kidney disease complications, aiming to reduce hospitalizations and dialysis needs.
- Medtronic’s Example: They’re combining AI and smart monitoring technologies to provide intelligent health management solutions for patients with chronic diseases.
Why this shift?
- It helps them avoid the challenges of Jicai, as these solutions are more complex and personalized, making them less susceptible to price comparisons.
- It enhances patient loyalty; chronic diseases require long-term management, and those who control this data and provide comprehensive care will have more influence.
- It opens up new profit opportunities in a context where profits from traditional drugs are declining.
In other words, multinational companies are transitioning from being mere drug sellers to providers of comprehensive health services.
---
5. Long-Term Investing: Why Are the Giants Investing Billions?
The news concludes with AstraZeneca’s plan to invest over 100 billion yuan in China by 2030. This is a huge commitment. Why would they invest so much?
- Trust in the Market: Bayer calls it a “long-term victory for those with a long-term vision.”
- Reasons for Confidence:
- Market Potential: China’s large population and accelerating aging mean a steady demand for innovative drugs and high-end devices.
- Innovation Momentum: China’s R&D capabilities, clinical resources, and supply chains can support global-level innovation.
- Policy Support: Despite Jicai, the government’s support for genuine innovation is clear (e.g., preferential treatment for innovative drugs through medical insurance negotiations and the role of the CIIE as a platform for innovation).
What does this mean for the future? Multinational companies are investing in R&D centers, production bases, and a full value chain in China because they see it as the core driver of global growth over the next 10–20 years. Their strategy reflects a shift from a short-term profit focus to a long-term partnership with China.
The phrase “In China, for China, benefiting the world” (Boehringer Ingelheim’s slogan) accurately captures this situation:
- In China: Leveraging China’s resources and efficiency.
- For China: Meeting the needs of Chinese patients and adapting to local policies.
- Benefiting the World: Products and technologies developed in China will benefit global markets.
---
Summary
For ordinary people, this means:
1. Cheaper Drugs and More Choices: Jicai continues to drive down prices of traditional drugs, while innovative drugs are quickly made available through local production and insurance coverage.
2. Smarter Services: Future medical devices and drugs will integrate AI and big data to provide more personalized health management.
3. Enhanced China’s Status: China is no longer just a consumer in the global pharmaceutical market; it’s becoming a key player and contributor to innovation. This will also drive the advancement of China’s local pharmaceutical industry and talent ecosystem.
In conclusion, multinational pharmaceutical companies in China are undergoing a profound transformation from harvesting market profits to co-creating innovation benefits. This transformation is not only a sign of the maturity of China’s pharmaceutical industry but also a crucial step in reshaping the global pharmaceutical landscape.